OBJECTIVE: An accumulating body of research suggests that former heroin abusers in methadone maintenance therapy (MMT) exhibit deficits in cognitive function. Whether these deficits are present in former methadone maintained patients following discontinuation of MMT is unknown. This study tests the hypothesis that former heroin users who have detoxified from methadone maintenance therapy and are drug-free have less pronounced cognitive impairment than patients continuing long-term MMT. METHOD: A series of neuropsychological tests were administered to three groups of subjects: 29 former heroin addicts receiving methadone maintenance treatment, 27 former heroin addicts withdrawn from all opiates, and 29 healthy controls without a history of drug dependence. Testing included Wechsler Adult Intelligence Scale-Revised Vocabulary Test, the Stroop Color-Word Test, the Controlled Oral Word Association Test, the Benton Visual Retention Test, and a Substance Use Inventory. FINDINGS: Both methadone-maintained and abstinent subject groups performed worse than controls on tasks that measured verbal function, visual-spatial analysis and memory, and resistance to distractibility. Abstinent subjects performed worse than their methadone maintained counterparts on tests measuring visual memory and construct formation. Cognitive impairment did not correlate with any index of drug use. CONCLUSIONS: We confirmed previous findings of neuropsychological impairment in long-term MMT recipients. Both patients receiving MMT and former heroin users in prolonged abstinence exhibited a similar degree of cognitive impairment. Cognitive dysfunction in patients receiving methadone maintenance may not resolve following methadone detoxification.
OBJECTIVE: An accumulating body of research suggests that former heroin abusers in methadone maintenance therapy (MMT) exhibit deficits in cognitive function. Whether these deficits are present in former methadone maintained patients following discontinuation of MMT is unknown. This study tests the hypothesis that former heroin users who have detoxified from methadone maintenance therapy and are drug-free have less pronounced cognitive impairment than patients continuing long-term MMT. METHOD: A series of neuropsychological tests were administered to three groups of subjects: 29 former heroin addicts receiving methadone maintenance treatment, 27 former heroin addicts withdrawn from all opiates, and 29 healthy controls without a history of drug dependence. Testing included Wechsler Adult Intelligence Scale-Revised Vocabulary Test, the Stroop Color-Word Test, the Controlled Oral Word Association Test, the Benton Visual Retention Test, and a Substance Use Inventory. FINDINGS: Both methadone-maintained and abstinent subject groups performed worse than controls on tasks that measured verbal function, visual-spatial analysis and memory, and resistance to distractibility. Abstinent subjects performed worse than their methadone maintained counterparts on tests measuring visual memory and construct formation. Cognitive impairment did not correlate with any index of drug use. CONCLUSIONS: We confirmed previous findings of neuropsychological impairment in long-term MMT recipients. Both patients receiving MMT and former heroin users in prolonged abstinence exhibited a similar degree of cognitive impairment. Cognitive dysfunction in patients receiving methadone maintenance may not resolve following methadone detoxification.
Authors: J B Williams; M Gibbon; M B First; R L Spitzer; M Davies; J Borus; M J Howes; J Kane; H G Pope; B Rounsaville Journal: Arch Gen Psychiatry Date: 1992-08
Authors: Erin Cummins; Craig P Allen; Alexander Ricchetti; Emily Boughner; Kayla Christenson; Megan Haines; Cheryl L Limebeer; Linda A Parker; Francesco Leri Journal: Psychopharmacology (Berl) Date: 2012-01-19 Impact factor: 4.530
Authors: B K Bracken; G H Trksak; D M Penetar; W L Tartarini; M A Maywalt; C M Dorsey; S E Lukas Journal: Drug Alcohol Depend Date: 2012-04-30 Impact factor: 4.492
Authors: Zukhrofi Muzar; Reymundo Lozano; Andrea Schneider; Patrick E Adams; Sultana M H Faradz; Flora Tassone; Randi J Hagerman Journal: Am J Med Genet A Date: 2015-04-21 Impact factor: 2.802
Authors: George S Portugal; Ream Al-Hasani; Amanda K Fakira; Jose L Gonzalez-Romero; Zare Melyan; Jordan G McCall; Michael R Bruchas; Jose A Morón Journal: J Neurosci Date: 2014-01-08 Impact factor: 6.167
Authors: Marie Eikemo; Philipp P Lobmaier; Mads L Pedersen; Nikolaj Kunøe; Anna Maria Matziorinis; Siri Leknes; Monica Sarfi Journal: Neuropsychopharmacology Date: 2019-03-31 Impact factor: 7.853
Authors: Allison J Applebaum; Laura C Reilly; Jeffrey S Gonzalez; Mark A Richardson; Catherine L Leveroni; Steven A Safren Journal: AIDS Patient Care STDS Date: 2009-06 Impact factor: 5.078
Authors: Olga Rass; Bethea A Kleykamp; Ryan G Vandrey; George E Bigelow; Jeannie-Marie Leoutsakos; Maxine L Stitzer; Eric C Strain; Marc L Copersino; Miriam Z Mintzer Journal: Exp Clin Psychopharmacol Date: 2014-02-17 Impact factor: 3.157